Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Study Reveals Scope, Characteristics of Adverse Drug Reactions in General Population

By Wiley | October 19, 2016

In a study of 1000 adult patients with unplanned admission to a tertiary hospital in Singapore, the prevalence of adverse drug reactions (ADRs) at the time of admission was 12.4 percent, and the prevalence of ADRs causing admission to the hospital was 8.1 percent.

The most common ADRs were gastrointestinal-related, while the most common drug category causing ADRs were cardiovascular drugs.

Patients with ADRs had a longer length of stay in the hospital than those who did not (median 4 versus 3 days). Some of the ADRs may have been partially predictable based on patients’ genetics.

“This study is important because we have quantified the burden of clinically impactful ADRs in the general adult population in Singapore for the very first time. Furthermore, results of this study provide essential directions to future pharmacogenomic research for reduction of ADR-related hospitalizations in Singapore,” said Professor Alexandre Chan, co-senior author of theBritish Journal of Clinical Pharmacology study.

Studies based on medical records review in the UK and other countries have reported that the prevalence of hospital admissions caused by ADRs range from 2.3 percent to 21.2 percent, and that a substantial proportion of these ADRs are potentially preventable.


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE